People with severe immunocompromise are recommended to receive COVID-19 vaccine

People with severe immunocompromise who have not previously received a COVID-19 vaccine are recommended to receive 2 primary doses and can consider at 3rd based on individual risk-benefit assessment. All primary doses should be given at least 8 weeks apart. A person may be vaccinated 3 to 4 weeks after the last primary dose in exceptional circumstances, such as before starting new immunosuppressant therapy, before overseas travel or if someone cannot reschedule vaccination easily (such as in an outreach vaccination program).

Adults aged ≥75 years are recommended further doses of COVID-19 vaccine every 6 months.

Adults aged 18–74 years with severe immunocompromise are recommended further doses of COVID-19 vaccine every 12 months and can consider a dose every 6 months based on individual risk-benefit assessment.

Children, and adolescents with severe immunocompromise aged 5 to <18 years can consider a further dose every 12 months based on a risk benefit assessment.

Infants and children aged 6 months to <5 years are not recommended further doses.

Comirnaty JN.1 and Omicron XBB.1.5-based vaccines can be used in infants, children, adolescents and adults.

Adolescents and adults may receive Comirnaty JN.1 ≥12 years formulation (dark grey cap) and Comirnaty Omicron XBB.1.5 ≥12 years formulation (dark grey cap), and children aged 5 to <12 years can receive Comirnaty JN.1 5 to <12 years formulation (light blue cap) and Comirnaty Omicron XBB.1.5 5 to <12 years formulation (light blue cap).

Infants and children aged 6 months to <5 years can receive Comirnaty JN.1 <5 years formulation (yellow cap) and Comirnaty Omicron XBB.1.5 6 months to <5 years formulation (maroon cap).